Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060980 · ClinicalTrials.gov registry record · Phase 3
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
NCT03060980 is a Phase 3 study that was terminated before completion, run by Intarcia Therapeutics. The registered enrollment target is 245 participants.
The verdict
NCT03060980, a Phase 3 study, was terminated before completion, sponsored by Intarcia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
Study Summary
A Phase 3b, open-label, randomized, multicenter, efficacy, safety, and tolerability study of ITCA 650 compared to Empagliflozin and to Glimepiride, as add-on therapy to Metformin in patients with Type 2 diabetes.
Interventions
- DRUG Empagliflozin (oral)
- DRUG ITCA 650 20/60 mcg/day
- DRUG Glimepiride (oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2017-03-03 |
| Est. Completion | 2018-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03060980
The ClinicalTrials.gov registry entry for NCT03060980 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Empagliflozin (oral) is the first listed.
NCT03060980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03060980 about?
NCT03060980 is a clinical study titled "Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin". A Phase 3b, open-label, randomized, multicenter, efficacy, safety, and tolerability study of ITCA 650 compared to Empagliflozin and to Glimepiride, as add-on therapy to Metformin in patients with Type 2 diabetes.
What is the current status of trial NCT03060980?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2017-03-03. Estimated completion is 2018-01-26.
What interventions are being tested in trial NCT03060980?
The interventions under investigation include: Empagliflozin (oral) (DRUG), ITCA 650 20/60 mcg/day (DRUG), Glimepiride (oral) (DRUG).
Who is sponsoring clinical trial NCT03060980?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.